FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
o Section 16. Form 4 or Form 5
bligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per resp	onse: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Blume-Jensen Peter					2. Issuer Name and Ticker or Trading Symbol Acrivon Therapeutics, Inc. [ACRV]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)		(Firs	t) (N	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/14/2023									v Offic	Officer (give title Other (specify below) President and CEO			(specify	
480 ARSENAL WAY, SUITE 100					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WATER	ΓOWN	MA	. 0	2472												Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(Stat	re) (Z	Zip)		Rul	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a corsatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruct																				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,			<i>'</i>	3. Transaction Code (Instr. 8) 4. Securities Acquired Disposed Of (D) (Instr. 5)				Benefic Owned	ies Forn ially (D) of Following (I) (I		: Direct	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
Common Stock 11/14/20				023				F ⁽¹⁾		239,023	D	\$5.0	08 2,658,673			D				
Common	Stock														1 210 005 1 1 1				See footnote ⁽²⁾	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				Transaction of Code (Instr. 8) Se Ac (A) Di:		of Deriv Secu Acqu (A) of Dispo	ired r osed) r. 3, 4	6. Date Expira (Monti	tion D		Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
						Code	v	(A)	(D)	Date Exercisable		Expiration Date		of Shares						

Explanation of Responses:

- 1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- 2. These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact

11/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.